US panel endorses animal efficacy of HGS' raxibacumab but FDA cites data quality issues
This article was originally published in Scrip
Executive Summary
Animal efficacy data for Human Genome Sciences' investigational anthrax therapeutic ABthrax (raxibacumab injection) predict a treatment response in humans with the inhalational form of the disease, the US FDA's outside advisors said in a 16 to seven vote, with one abstention.